NewAmsterdam Pharma Q3 EPS $(0.61) Misses $(0.41) Estimate, Sales $348.000K Miss $5.287M Estimate
Benzinga Newsdesk 12 months ago
EarningsEarnings MissesNews
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.41) by 47.34 percent. This is a 238.89 percent decrease over losses of $(0.18) per share
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.41) by 47.34 percent. This is a 238.89 percent decrease over losses of $(0.18) per share from the same period last year. The company reported quarterly sales of $348.000 thousand which missed the analyst consensus estimate of $5.287 million by 93.42 percent. This is a 98.80 percent decrease over sales of $29.111 million the same period last year.